Sight Sciences, Inc. (SGHT)
After hours:
| Previous close | 6.10 |
| Open | 6.05 |
| Bid | 6.04 x 800 |
| Ask | 6.65 x 800 |
| Day's range | 6.04 - 6.65 |
| 52-week range | 5.98 - 27.70 |
| Volume | |
| Avg. volume | 216,311 |
| Market cap | 303.696M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 11 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
- GlobeNewswire
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical OphthalmologyStudy authors concluded that the TearCare procedure delivered superior symptoms improvements over LipiFlow in patients suffering from advanced dry eye disease. These patients experienced significantly better symptoms improvements, quality of vision, and symptom frequency MENLO PARK, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT
- GlobeNewswire
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting
First-time Preview of the Ergo-Series of the OMNI® Surgical System and Exhibition of the New SION™ Surgical Instrument to be Showcased at AAO Booth 4843MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO convention at McCormick Place in Chicago, IL. Mee
- GlobeNewswire
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
Compendium of clinical presentations includes studies with up to 3.5 years of patient follow-up and over 400 eyes treated in 31 centers in both combination cataract and standalone useMENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Milan, Italy on Friday, September 16 through Tuesday
